Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Estrogen-Progestogen Therapy (EPT)
Treatment for Menopause
Typical Dosage: Oral Estradiol 0.5-1mg daily with progestogen (e.g., Micronized Progesterone 100-200mg daily or cyclically)
Effectiveness
90%
Safety Score
60%
Clinical Trials
1
Participants
500K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Oral Estradiol 0.5-1mg daily with progestogen (e.g., Micronized Progesterone 100-200mg daily or cyclically)
Time to Effect
1-4 weeks
Treatment Duration
2-5 years, reassess
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$875
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$45,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$1,029.41
Cost per Remission
$1,346.15
Estrogen-Progestogen Therapy (EPT) Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+65%
Common Side Effects
Breast tenderness
+25%
Nausea
+8%
Headache
+12%
Vaginal bleeding/spotting
+15%
Bloating
+10%
Increased risk of VTE
+0.03%
Increased risk of breast cancer (long-term use)
+0.05%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Estrogen-Progestogen Therapy (EPT) in Menopause
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
NCT03921736COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Started: Jan 10, 2000